HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma

Zhang, Zijian; Cao, Yimei; Zhao, Weiming; Guo, Lei; Liu, Wanpeng

doi:10.3233/cbm-160298

Cited by 17 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Absence of the primary cilium has also been reported in other tumor types, such as cancer of the pancreas [38], ovary [14], lung [12], kidney [39], and melanoma [40]. In addition, these tumors present overexpression of HDAC6 [40][41][42][43][44], like glioblastoma, which reinforces the hypothesis that the primary cilium disappears due to overexpression of HDAC6.…”

Section: Expression Of Hdac6 and Mesenchymal And Autophagic Markers In Glioblastoma Samples And Cell Linessupporting

confidence: 66%

Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines

Urdiciain

Erausquin

Zelaya

et al. 2021

Biology

View full text Add to dashboard Cite

Glioblastoma multiforme, the most common type of malignant brain tumor as well as the most aggressive one, lacks an effective therapy. Glioblastoma presents overexpression of mesenchymal markers Snail, Slug, and N-Cadherin and of the autophagic marker p62. Glioblastoma cell lines also present increased autophagy, overexpression of mesenchymal markers, Shh pathway activation, and lack of primary cilia. In this study, we aimed to evaluate the role of HDAC6 in the pathogenesis of glioblastoma, as HDAC6 is the most overexpressed of all HDACs isoforms in this tumor. We treated glioblastoma cell lines with siHDAC6. HDAC6 silencing inhibited proliferation, migration, and clonogenicity of glioblastoma cell lines. They also reversed the mesenchymal phenotype, decreased autophagy, inhibited Shh pathway, and recovered the expression of primary cilia in glioblastoma cell lines. These results demonstrate that HDAC6 might be a good target for glioblastoma treatment.

show abstract

Section: Expression Of Hdac6 and Mesenchymal And Autophagic Markers In Glioblastoma Samples And Cell Linessupporting

confidence: 66%

Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines

Urdiciain

Erausquin

Zelaya

et al. 2021

Biology

View full text Add to dashboard Cite

show abstract

“…Furthermore, a The Cancer Genome Atlas (TCGA) dataset analysis associated high HDAC1 mRNA levels with ccRCC worse overall survival [108]. Furthermore, high HDAC6 expression levels were displayed by high grade RCC and were shown to be an independent poor prognostic factor [109]. Paradoxically, although ccRCC samples depict lower HDAC9 levels than normal adjacent tissues, high HDAC9 expression was associated with poor prognosis [110].…”

Section: Epigenetic Mechanismsmentioning

confidence: 99%

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma

Lameirinhas

Miranda-Gonçalves

Henrique

et al. 2019

Genes

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common malignancy affecting the kidney. Current therapies are mostly curative for localized disease, but do not completely preclude recurrence and metastization. Thus, it is imperative to develop new therapeutic strategies based on RCC biological properties. Presently, metabolic reprograming and epigenetic alterations are recognized cancer hallmarks and their interactions are still in its infancy concerning RCC. In this review, we explore RCC biology, highlighting genetic and epigenetic alterations that contribute to metabolic deregulation of tumor cells, including high glycolytic phenotype (Warburg effect). Moreover, we critically discuss available data concerning epigenetic enzymes’ regulation by aberrant metabolite accumulation and their consequences in RCC emergence and progression. Finally, we emphasize the clinical relevance of uncovering novel therapeutic targets based on epigenetic reprograming by metabolic features to improve treatment and survival of RCC patients.

show abstract

“…One such enzyme is histone deacetylase 6 (HDAC6), which is localized predominantly in the cytoplasm and controls nonhistone acetylation, such as that of α-tubulin ( Li C. et al, 2018 ). High expression levels of HDAC6 have been detected in numerous types of cancer and such expression is strongly associated with a poor overall survival rate ( Zhang et al, 2017 ; Li T. et al, 2018 ). HDAC6 regulates essential biological processes in cancer through α-tubulin deacetylation ( Li C. et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Emerging role of microtubule-associated proteins on cancer metastasis

Wattanathamsan

Pongrakhananon

2022

Front. Pharmacol.

View full text Add to dashboard Cite

The major cause of death in cancer patients is strongly associated with metastasis. While much remains to be understood, microtubule-associated proteins (MAPs) have shed light on metastatic progression’s molecular mechanisms. In this review article, we focus on the role of MAPs in cancer aggressiveness, particularly cancer metastasis activity. Increasing evidence has shown that a growing number of MAP member proteins might be fundamental regulators involved in altering microtubule dynamics, contributing to cancer migration, invasion, and epithelial-to-mesenchymal transition. MAP types have been established according to their microtubule-binding site and function in microtubule-dependent activities. We highlight that altered MAP expression was commonly found in many cancer types and related to cancer progression based on available evidence. Furthermore, we discuss and integrate the relevance of MAPs and related molecular signaling pathways in cancer metastasis. Our review provides a comprehensive understanding of MAP function on microtubules. It elucidates how MAPs regulate cancer progression, preferentially in metastasis, providing substantial scientific information on MAPs as potential therapeutic targets and prognostic markers for cancer management.

show abstract

HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma

Abstract: These analyses showed that high HDAC6 expression was an independent, poor prognostic factor in patients with RCC, and HDAC6 could serve as a biomarker of RCCs prognostic and an indicator for RCC progression.

Cited by 17 publications

References 23 publications

Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines

Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma

Emerging role of microtubule-associated proteins on cancer metastasis

Contact Info

Product

Resources

About